FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jose Miguel Sanchez

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Physiology

Co-author Network

Publications

TOP 3
Pilar Garrido; José Luis González-Larriba; Amelia Insa; Mariano Provencio; Antonio Torres; Dolores Isla; Jose Miguel Sanchez; Felipe Cardenal; Manuel Domine; Jose Ramon Barcelo; Vicente Tarrazona; Andres Varela; Rafael Aguilo; Julio Astudillo; Ignacio Muguruza; Angel Artal; Florentino Hernando-Trancho; Bartomeu Massuti; Maria Sanchez-Ronco; Rafael Rosell
Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901.
Manuel Cobo; Dolores Isla; Bartomeu Massuti; Ana Montes; Jose Miguel Sanchez; Mariano Provencio; Núria Viñolas; Luis Paz-Ares; Guillermo Lopez-Vivanco; Miguel Angel Muñoz; Enriqueta Felip; Vicente Alberola; Carlos Camps; Manuel Domine; Jose Javier Sanchez; Maria Sanchez-Ronco; Kathleen D Danenberg; Miquel Taron; David R Gandara; Rafael Rosell
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
Rafael Rosell; Fabiana Cecere; Francesco Cognetti; Mauricio Cuello; Jose Miguel Sanchez; Miquel Taron; Noemi Reguart; David M Jablons
Future directions in the second-line treatment of non-small cell lung cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jose Miguel Sanchez (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2007: Pilar Garrido; José Luis González-Larriba; Amelia Insa; Mariano Provencio; Antonio Torres; Dolores Isla; Jose Miguel Sanchez; Felipe Cardenal; Manuel Domine; Jose Ramon Barcelo; Vicente Tarrazona; Andres Varela; Rafael Aguilo; Julio Astudillo; Ignacio Muguruza; Angel Artal; Florentino Hernando-Trancho; Bartomeu Massuti; Maria Sanchez-Ronco; Rafael Rosell
Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(30):4736-42.
2007: Manuel Cobo; Dolores Isla; Bartomeu Massuti; Ana Montes; Jose Miguel Sanchez; Mariano Provencio; Núria Viñolas; Luis Paz-Ares; Guillermo Lopez-Vivanco; Miguel Angel Muñoz; Enriqueta Felip; Vicente Alberola; Carlos Camps; Manuel Domine; Jose Javier Sanchez; Maria Sanchez-Ronco; Kathleen D Danenberg; Miquel Taron; David R Gandara; Rafael Rosell
Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(19):2747-54.
2006: Rafael Rosell; Fabiana Cecere; Francesco Cognetti; Mauricio Cuello; Jose Miguel Sanchez; Miquel Taron; Noemi Reguart; David M Jablons
Future directions in the second-line treatment of non-small cell lung cancer.
Seminars in oncology 2006;33(1 Suppl 1):S45-51.
2005: José Luis Ramirez; Rafael Rosell; Miquel Taron; Maria Sanchez-Ronco; Vicente Alberola; Ramon de las Peñas; Jose Miguel Sanchez; Teresa Moran; Carlos Camps; Bartomeu Massuti; Jose Javier Sanchez; Fernanda Salazar; Silvia Catot
14-3-3sigma methylation in pretreatment serum circulating DNA of cisplatin-plus-gemcitabine-treated advanced non-small-cell lung cancer patients predicts survival: The Spanish Lung Cancer Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(36):9105-12.
2005: Rafael Rosell; Manuel Cobo; Dolores Isla; Jose Miguel Sanchez; Miquel Taron; Giuseppe Altavilla; Mariacarmela Santarpia; Teresa Moran; Silvia Catot; Olatz Etxaniz
Applications of genomics in NSCLC.
Lung cancer (Amsterdam, Netherlands) 2005;50 Suppl 2():S33-40.
2005: Rafael Rosell; Yukito Ichinose; Miquel Taron; Carme Sarries; Cristina Queralt; Pedro Méndez; Jose Miguel Sanchez; Ken-Ichi Nishiyama; Teresa Moran; Beatriz Cirauqui; José-Luis Mate; Benjamin Besse; Noemi Reguart; Maria Perez; Jose Javier Sanchez
Mutations in the tyrosine kinase domain of the EGFR gene associated with gefitinib response in non-small-cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2005;50(1):25-33.
2005: Miquel Taron; Yukito Ichinose; Rafael Rosell; Tony Shu Kam Mok; Bartomeu Massuti; Lurdes Zamora; José-Luis Mate; Christian Manegold; Mayumi Ono; Cristina Queralt; Thierry jahan; Jose Javier Sanchez; Maria Sanchez-Ronco; Victor Hsue; David M Jablons; Jose Miguel Sanchez; Teresa Moran
Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in gefitinib-treated chemorefractory lung adenocarcinomas.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(16):5878-85.
2005: Carlos Camps; Enriqueta Felip; Jose Miguel Sanchez; Bartomeu Massuti; Angel Artal; Luis Paz-Ares; Alfredo Carrato; Vicente Alberola; Ana Blasco; José Baselga; L Astier; Maurizio Voi; Rafael Rosell
Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(4):597-601.
2005: Enriqueta Felip; Miquel Taron; Rafael Rosell; Pedro Méndez; Cristina Queralt; Maria Sanchez Ronco; Jose Javier Sanchez; Jose Miguel Sanchez; Jose Maestre; Joaquim Majo
Clinical significance of hypoxia-inducible factor-1a messenger RNA expression in locally advanced non-small-cell lung cancer after platinum agent and gemcitabine chemotherapy followed by surgery.
Clinical lung cancer 2005;6(5):299-303.
2004: Rafael Rosell; Miquel Taron; Jose Miguel Sanchez; Teresa Moran; Noemi Reguart; Benjamin Besse; Dolores Isla; Bartomeu Massuti; Vicente Alberola; Jose Javier Sanchez
The promise of pharmacogenomics: gemcitabine and pemetrexed.
Oncology (Williston Park, N.Y.) 2004;18(13 Suppl 8):70-6.
2004: Miquel Taron; Rafael Rosell; Enriqueta Felip; Pedro Méndez; John Souglakos; Maria Sanchez Ronco; Cristina Queralt; Joaquim Majo; Jose Miguel Sanchez; Jose Javier Sanchez; Jose Maestre
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.
Human molecular genetics 2004;13(20):2443-9.
2004: Rafael Rosell; Jose Miguel Sanchez; Miquel Taron; Teresa Moran; Beatriz Ciuraqui; Mercedes Canela; Enriqueta Felip; Bartomeu Massuti; Carlos Camps
Pemetrexed in previously treated non-small-cell lung cancer.
Oncology (Williston Park, N.Y.) 2004;18(8 Suppl 5):63-71.
2003: José Luis Ramirez; Carme Sarries; Pedro Lopez de Castro; Barbara Roig; Cristina Queralt; Daniel Escuin; Itziar de Aguirre; Jose Miguel Sanchez; Jose Luis Manzano; Mireia Margelí; Jose Javier Sanchez; Julio Astudillo; Miquel Taron; Rafael Rosell
Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients.
Cancer letters 2003;193(2):207-16.
2002: Albert Font; Jose Miguel Sanchez; Rafael Rosell; Miquel Taron; E Martinez; Mónica Guillot; Jose Luis Manzano; M Margeli; Agustí Barnadas; Albert Abad
Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
Lung cancer (Amsterdam, Netherlands) 2002;37(2):213-8.
2001: Rafael Rosell; Enriqueta Felip; Jose Maestre; Jose Miguel Sanchez; Jose Javier Sanchez; Jose Luis Manzano; Julio Astudillo; Miquel Taron; Mariano Monzo
The role of chemotherapy in early non-small-cell lung cancer management.
Lung cancer (Amsterdam, Netherlands) 2001;34 Suppl 3():S63-74.